Oral abstract
Pharmacological treatment
AS-58: What Is the Optimal Triple Antiplatelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-Eluting Stents Implantation?

https://doi.org/10.1016/j.amjcard.2010.01.094Get rights and content

Section snippets

Background

Triple antiplatelet therapy has been reported to be superior to dual antiplatelet therapy in acute myocardial infarction (AMI) patients. However, optimal triple antiplatelet therapy duration (TAD) remains unclear.

Methods

We retrospectively analyzed 716 patients with AMI undergoing DES implantation between November 2005 and May 2008. We excluded patients who had suffered major adverse cardiac events (MACE; defined as the composite of cardiac death, nonfatal AMI, stent thrombosis, and target vessel revascularization [TVR]) for 3 months after index procedures.

Results

Patients were assigned in groups based on TAD as follows: 1–30 days (group I; n = 265, mean duration [MD] 18.15 ± 7.26 days), 1–3 months (group II; n = 232, MD 52.31 ± 15.55 days), 3–6 months (group III; n = 86, MD 129.21 ± 25.44 days), and >6 months (group IV; n = 133, MD 317.02 ± 75.38 days). The mean age was higher in group II than those of the other groups. Group III included more men, and group IV included more diabetics and current smokers. There were no significant differences in

Conclusion

Our data show that longer TAD is not always associated with better clinical outcomes. However, TAD of ≥3 months appears more effective in patients with AMI undergoing DES implantation.

References (0)

Cited by (0)

View full text